ClinicalTrials.gg
Active, not recruitingNCT06888687CARE-T2DUpdated Nov 17, 2026

Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.

An interventional study of Dietetic support and Continuous glucose monitoring in Type 2 Diabetes Mellitus (T2DM), Continuous Glucose Measurement and Dietary Modification, sponsored by Australian Catholic University. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Australian Catholic University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Study documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia — 24 open to participants now, 30 under way, 13 of them phase 3. Diabetes Mellitus, Type 2 · Australia.

Enrollment
174th of 246
160 · median 392
Started
2025
with 8 others
No phase
31 of 262
4 open now
Primary completion
2026-11
later than 7 of 29 live
Registered
238th of 262
by date

Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, this one is the 174th largest by enrollment of the 246 interventional ones that give a count, is one of 9 that started in 2025, is one of 31 with no phase, reaches primary completion later than 7 of the 29 other live ones, and was the 238th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

24 of the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, or all of them as a file.
02

Study summary

A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.

Read the detailed description

In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via REDCap) have been collected, participants will be randomised into one of two groups (DIET, dietetic support only; CGMD, CGM plus dietetic support). All participants will receive four (4) dietetic consults via telehealth at weeks 2, 6, 10 and 16, the content of which will be related to the randomised condition. Measurements will be repeated at 3 and 6 months from baseline to assess the changes in primary and secondary outcomes.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Continuous Glucose Measurement
  • Dietary Modification

Keywords

  • Continual Glucose Monitoring
  • Type 2 Diabetes
  • Non-insulin dependant Diabetes
  • Dietitian Support
  • Health Behaviours
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18+ years
  • Reside anywhere in Australia and have a postal address
  • Confirmed T2D diagnosis by a GP/endocrinologist
  • Current of ≥7.0%
  • Have a smartphone and able to independently use it

Exclusion criteria

Exclusion Criteria:

  • Under the age of 18 years
  • Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. )
  • Use of CGM within the last six months
  • Eating Disorder Examination Questionnaire (EDE-Q) global score >2.8 OR global score > or equal to 1.52, with sum of Q14-18 > or equal to 4
  • Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
  • Not weight stable (>5 kg change over last three months)
  • Severe hypoglycaemic event (i.e. requiring assistance) within last six months
  • Change of antihyperglcyaemic medications within last three months
  • Women who are pregnant or breastfeeding (within 24 weeks)
  • History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
  • History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome ()
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Active comparator
    Dietetic support only

    This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.

    Behavioral: Dietetic support

  • Experimental
    CGM plus dietetic support

    The CGM plus dietetic support group will be provided 'standard care' dietetic support alongside the use, and interpretation of, the CGM data collected to assist in the understanding of dietary modifications on glucose management. As per the DIET group, dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. The CGM data collected via LibreLink will be used by both the participant and the dietitian to inform dietary modifications.

    Behavioral: Dietetic support · Device: Continuous glucose monitoring

Interventions

  • BehavioralDietetic support

    Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.

  • DeviceContinuous glucose monitoring

    Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use.

06

What researchers measure

Primary outcomes

  1. HbA1c

    Glycated haemoglobin concentration

    Time frame: baseline, 6 months

Secondary outcomes

  1. HbA1c

    Glycated haemoglobin concentration

    Time frame: 3 months

  2. 24 h assessment of glycaemia

    24 h glucose measures assessed by blinded CGM (including, but not limited to, time in range, CV)

    Time frame: baseline, 6 months

Other outcomes

  1. CGM application and use

    number of days of CGM use and interaction with viewing CGM data (via LibreLink); CGMD group ony

    Time frame: From 0 to 26 weeks, per 2 week period of sensor use

  2. Per protocol analysis

    Primary analysis of the primary outcome (0-6 months HbA1c) is going to be intention to treat. Therefore, secondary analysis of all other variables will be a per-protocol (PP) analysis. Inclusion in PP analysis will be defined by: 1\. Attendance at ≥3 dietetic consults, within ±10 days of the designated 2-, 6-, 10- and 16-week time points.

    Time frame: 6 months

  3. Dietary intake

    energy and macronutrient composition calculated from food records

    Time frame: baseline, 3 months, 6 months

  4. Fasting blood glucose

    fasting blood glucose concentrations

    Time frame: baseline, 3 months, 6 months

  5. Adherence

    measures of adherence assessed by self-report (questionnaire)

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks

  6. hs-CRP

    fasting high sensitive C-Peptide concentrations

    Time frame: baseline, 3 months, 6 months

  7. Fasting cholesterol

    Fasting cholesterol concentrations (total, HDL and LDL)

    Time frame: baseline, 3 months, 6 months

  8. Fasting lipid concentration

    fasting triglyceride concentrations

    Time frame: baseline, 3 months, 6 months

  9. Medication effect score (MES)

    Medication effect score for antihyperglycemic medications

    Time frame: baseline, 6 months

  10. Participant experience

    Qualitative semi-structured interviews

    Time frame: 6 months

  11. Physical activity

    Self-reported questionnaire (International Physical Activity Questionnaire (IPAQ) - Long Form)

    Time frame: baseline, 3 months, 6 months

  12. Sleep quality and quantity

    Self-reported questionnaire (Pittsburgh Sleep Quality Index (PSQI))

    Time frame: baseline, 3 months, 6 months

  13. Eating behaviours

    Self-reported questionnaire (Eating Disorders Examination Questionnaire (EDEQ))

    Time frame: baseline, 3 months, 6 months

  14. Health literacy

    self-reported questionnaire (Health Literacy Questionnaire (HLQ))

    Time frame: baseline, 3 months, 6 months

  15. Dietary quality

    Assessed using the Healthy Eating Index For Australian adults (HEIFA)

    Time frame: baseline, 3 months, 6 months

  16. Diabetes self-management

    Self-reported questionnaire (Diabetes Self-Management Questionnaire (DSMQ-R))

    Time frame: baseline, 3 months, 6 months

  17. Diabetes distress

    Self-reported questionnaire (Type 2 Diabetes Distress Assessment Scale (T2DDAS))

    Time frame: baseline, 3 months, 6 months

  18. Overall well-being

    Self-reported questionnaire (WHO-5)

    Time frame: baseline, 3 months, 6 months

  19. Diabetes-specific well-being

    Self-reported questionnaire (DAWN Impact of Diabetes Profile (DIDP-7))

    Time frame: baseline, 3 months, 6 months

  20. Treatment satisfaction

    self-reported questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQs (status) and DTSQc (change)))

    Time frame: baseline, 3 months, 6 months

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.

Supporting information: Study protocol

Access criteria: Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 21, 2025
StartActual
May 12, 2025
Primary completionEst.
Nov 28, 2026
CompletionEst.
Nov 28, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Show all 1 update
  1. Nov 17, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06888687
Lead sponsor
Australian Catholic University
Collaborators
Abbott Diabetes Care, University of Adelaide, The University of Queensland, Monash University, University of Melbourne, Deakin University
Responsible party
Evelyn Parr (Principal Investigator, Australian Catholic University) — Principal investigator
First posted
Mar 21, 2025
Start date
May 12, 2025
Primary completion
Nov 28, 2026 (estimated)
Completion
Nov 28, 2026 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion